Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725137 | 0.82 | PARP10 (0.51) | PARP10PARP11GRM5PARP1JAK2 | |
| SCHEMBL23364331 | 0.81 | MKNK2 (0.43) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL31158991 | 0.79 | MKNK2 (0.42) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL3840001 | 0.79 | PARP10 (0.36) | CLK4NTRK1FLT3GSK3BPIM1 | |
| SCHEMBL29987052 | 0.78 | MKNK2 (0.41) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL24667786 | 0.78 | MKNK2 (0.41) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL13445139 | 0.78 | CLK4 (0.43) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL12951697 | 0.78 | KDR (0.37) | CLK4NTRK1FLT3GSK3BPIM1 | |
| SCHEMBL15727818 | 0.78 | MKNK2 (0.41) | MKNK2CLK4NTRK1FLT3GSK3B | |
| SCHEMBL24169597 | 0.78 | MKNK2 (0.41) | MKNK2CLK4NTRK1FLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116870-A1 | NOVEL NAV 1.1 POTENTIATORS | BOEHRINGER INGELHEIM INT (DE) | 2026-04-30 | — | — | US | disclosed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12410170-B2 | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | ARCUS BIOSCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| CN-114206332-B | 2,3, 5-Trisubstituted pyrazolo [1,5-A ] pyrimidine compounds | 艾库斯生物科学有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| CN-111433200-B | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410170-B2 | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | PIK3CA, PIK3CG, PIK3CD | MKNK2 130/4885CLK4 3599/4885NTRK1 4284/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MKNK2 579/4885CLK4 1737/4885NTRK1 1564/4885 |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | MKNK2 4497/4885CLK4 3699/4885NTRK1 3197/4885 |
| US-20260116870-A1 | NOVEL NAV 1.1 POTENTIATORS | SCN1B, SCN1A, CACNA1B | MKNK2 2889/4885CLK4 3595/4885NTRK1 2443/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MKNK2 105/4885CLK4 2096/4885NTRK1 1132/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MKNK2 240/4885CLK4 787/4885NTRK1 719/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MKNK2 579/4885CLK4 1737/4885NTRK1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.